OraSure boosted by AbbVie hep C testing deal
This article was originally published in Scrip
Executive Summary
Abbott spin-out AbbVie has agreed to co-promote Orasure Technologies' rapid hepatitis C virus (HCV) test in certain US markets. The long-awaited deal should "help dramatically accelerate uptake [of the test] in the US," according to Jefferies analyst Brandon Couillard, who described the news as "better late than never."